FDA says Molecular BioLife International sold Shark 2 Collagen and Balanced Kollagen as unapproved drugs with disease-treatment claims.
What happened
FDA reviewed www.molecularbiolife.com from March to April 2021 and found that the company takes orders there for Shark 2 Collagen and Balanced Kollagen. The website and linked white papers claimed the products treat or prevent diseases including cancer, arthritis, psoriasis, lupus, and other conditions, making them drugs under the Act.
What FDA found
The company marketed Shark 2 Collagen and Balanced Kollagen with website claims that they cure, treat, or prevent diseases, so FDA treats them as unapproved new drugs.
FD&C Act sections 201(g)(1)(B), 201(p), 301(d), and 505(a) [21 U.S.C. 321(g)(1)(B), 321(p), 331(d), 355(a)]The products were offered for diseases that laypeople cannot safely diagnose or treat without a licensed practitioner, so they lacked adequate directions for use and were misbranded.
FD&C Act section 502(f)(1) [21 U.S.C. 352(f)(1)]; 21 CFR 201.5Specific Shark 2 Collagen claims said shark collagen attacks cancer cells, shrinks tumors, and treats arthritis, psoriasis, lupus, eczema, and other diseases.
FD&C Act section 201(g)(1)(B) [21 U.S.C. 321(g)(1)(B)]Specific Balanced Kollagen claims said oral collagen prevents chronic illness, joint disorders, heart disease, and certain cancers, and eases osteoarthritis and CJD symptoms.
FD&C Act section 201(g)(1)(B) [21 U.S.C. 321(g)(1)(B)]Introducing these misbranded drugs into interstate commerce violates the Act.
FD&C Act section 301(a) [21 U.S.C. 331(a)]
What FDA wants
FDA asks the company to notify it in writing within 15 working days of the steps taken to correct the violations and prevent recurrence, including documentation. If corrective actions cannot be completed in that time, the company must explain the delay and state when it will finish.
Who should pay attention
- dietary supplement brands and online marketers that make disease claims
- retailers and distributors selling collagen or joint-health supplements
- consumers who rely on supplement websites for treatment advice
This is a summary. Read the original letter on fda.gov.